San Diego-primarily based Viking Therapeutics marked alone as a serious competitor from the weight loss drug marketplace in February just after revealing promising knowledge from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March the